Under-utilisation of β-blockers after acute myocardial infarction. Pharmacoeconomic implications

PharmacoEconomics

Volumn 15, Issue 3, 1999, Pages 257-268

  Bradford, W David ^a,b   Chen, Jersey ^b   Krumholz, Harlan M ^b,c,d  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Yale New Haven Ctr Outcomes Res/E   (United States)

^d Yale New Haven Ctr Outcomes Res ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ACUTE HEART INFARCTION; DRUG EFFICACY; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESOURCE MANAGEMENT; REVIEW; UNITED STATES;

ADRENERGIC BETA-ANTAGONISTS; DRUG UTILIZATION; HUMANS; MYOCARDIAL INFARCTION; UNITED STATES;

EID: 0033067845     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199915030-00005     Document Type: Review

References (34)

1. Snow PJD. Effect of propranolol in myocardial infarction. Lancet 1965; II: 551-3
2. Yusuf S, Peto P, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1986; 27 (5): 355-71
3. Hjalmarson Å. International beta-blocker review in acute and postmyocardial infarction. Am J Cardiol 1988; 61: 26B-9B
4. Goldstein S. β-Blockers in hypertensive and coronary heart disease. Arch Intern Med 1996; 156: 1267-76
5. Furberg CD, Byington RP. What do subgroup analyses reveal about differential response to beta-blocker therapy? Circulation 1983; 67: 198-101
6. Olsson G, Wikstrand J, Warnold I, et al. Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials. Eur Heart J 1992; 13: 28-32
7. Cruickshank JM, Prichard BNC. Beta-blockers in clinical practice. 2nd ed. New York (NY): Churchill Livingstone, 1994: 559-68
8. American College of Cardiology (ACC)/American Heart Association (AHA) guidelines for the management of patients with acute myocardial infarction. J Am Coll Cardiol 1996; 28 (5): 1328-428
9. Agusti A, Arnau JM, Laporte JR. Clinical trials versus clinical practice in the secondary prevention of myocardial infarction. Eur J Clin Pharmacol 1994; 46: 95-9
10. Whitford DL, Southern AJ. Audit of secondary prophylaxis after myocardial infarction. BMJ 1994; 309: 1268-9
11. Rogers WJ, Bowlby LJ, Nisha CC, et al. Treatment of myocardial infarction in the United States (1990 to 1993). Circulation 1994; 90: 2103-14
12. Soumerai SB, McLaughlin T, Spiegelman D, et al. Adverse outcomes of underuse of β-blockers in elderly survivors of acute myocardial infarction. JAMA 1997; 277: 115-21
13. Krumholz HM, Radford MJ, Wang Y, et al. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction. JAMA 1998; 280: 623-9
14. Meehan TP, Hennen J, Radford MJ, et al. Process and outcome of care for acute myocardial infarction among Medicare beneficiaries in Connecticut: a quality improvement demonstration project. Ann Intern Med 1995; 122: 928-36
15. Pilote L, Califf RM, Sapp S, et al. Regional variation across the United States in the management of acute myocardial infarction. N Engl J Med 1995; 333: 565-72
16. Woods KL, Ketley A, Lowy A, et al. Beta-blockers and anti-thrombotic treatment for secondary prevention after acute myocardial infarction. European Heart Journal 1998; 19: 74-79
17. Fishkind D, Paris BEC, Aronow WS. Use of digoxin, diuretics, beta blockers, angiotensin-converting enzyme inhibitors and calcium channel blockers in older patients in an academic hospital-based geriatrics practice. J Am Geriatr Soc 1997; 45: 809-12
18. Gurwitz JH, Goldberg RJ, Chen Z, et al. β-locker therapy in acute myocardial infarction: evidence for under-utilization in the elderly. Am J Med 1992; 93: 605-19
19. Montague TJ, Ikuta RM, Wong RY, et al. Comparison of risk and patterns of practice in patients older and younger than 70 years with acute myocardial infarction in a two-year period (1987-1988). Am J Cardiol 1991; 68: 843-7
20. Aronow WS. Prevalence of use of beta blockers and of calcium channel blockers in older patients with prior myocardial infarction at the time of admission to a nursing home. J Am Geriatr Soc 1996; 44: 1075-7
21. Sial SH, Malone M, Freeman JL, et al. Beta blocker use in the treatment of community hospital patients discharged after myocardial infarction. J Gen Intern Med 1994; 9: 599-605
22. Karlson BW, Herlitz J, Hjalmarson A. Impact of clinical trial on the use of beta blockers after acute myocardial infarction and its relation to other risk indicators for death and 1-year mortality rate. Clin Cardiol 1994; 17: 311-6
23. Pashos CL, Normand SLT, Garfinkel JB, et al. Trends in the use of drug therapy in patients with acute myocardial infarction: 1988 to 1992. J Am Coll Cardiol 1994; 23: 1023-30
24. O'Rourke RA. Are beta-blockers really underutilized in postinfarction patients? J Am Coll Cardiol 1995; 15: 1437-9
25. Viskin S, HV Barron. Beta blockers prevent cardiac death following a myocardial infarction: so why are so many infarct survivors discharged without beta blockers? Am J Cardiol 1996; 78: 821-2
26. Ellerbeck EF, Jenks SF, Radford MJ, et al. Quality of care for Medicare patients with acute myocardial infarction. JAMA 1995; 273: 1509-14
27. Avanzini F, Zuanetti G, Latini R, et al. Use of beta-blocking agents in secondary prevention after myocardial infarction: a case for evidence-based medicine? Eur Heart J 1997; 18: 1147-56
28. Woods KL, Ketley D, Lowy A, et al. Beta-blockers and anti-thrombotic treatment for secondary prevention of acute myocardial infarction. Eur Heart J 1998; 19: 74-9
29. Ayanian JZ, Hauptman PJ, Guadagnoli E, et al. Knowledge and practices of generalists and specialist physicians regarding drug therapy for acute myocardial infarction. N Engl J Med 1994; 331: 1136-42
30. Brand DA, Newcomer LN, Freiburger A, et al. Cardiologists' practices compared with practice guidelines: use of beta-blockade after acute myocardial infarction. J Am Coll Cardiol 1995; 26: 1432-6
31. Jollis JG, DeLong ER, Peterson ED, et al. Outcome of acute myocardial infarction according to the specialty of the admitting physician. N Engl J Med 1996; 335: 1880-7
32. Kennedy HL, Rosenson RS. Physician use of beta-andrenergic blocking therapy: a changing perspective. J Am Coll Cardiol 1995; 26 (2): 547-52
33. Goldman L, Sia STB, Cook EF, et al. Costs and effectiveness of routine therapy with long-term beta-andrenergic antagonists after acute myocardial infarction. N Engl J Med 1988; 319: 152-7
34. Kuntz KM, Lee TH. Cost-effectiveness of accepted measures for intervention in coronary heat disease. Coron Artery Dis 1995; 6: 472-8